Latham & Watkins Advises ALASTIN Skincare® on Acquisition by Galderma

A corporate team represents the physician-dispensed skincare brand in the transaction

November 29, 2021

Galderma, the world’s largest independent dermatology company, announced that it has signed a definitive agreement to acquire ALASTIN Skincare®, Inc. (ALASTIN), a specialty aesthetics company dedicated to developing innovative and clinically-tested physician-dispensed skincare products. The acquisition is subject to customary closing conditions and necessary regulatory approvals. 

Latham & Watkins LLP represents ALASTIN in the acquisition with a corporate team led by Orange County partner Daniel Rees and San Diego partner Cheston Larson with associates Madison Mapes, Claire Hutar, Mekbeb Hagos, and Erik Jensen. Advice was also provided on compensation and benefits matters by San Diego partner Holly Bauer with associate Mario Moreno; on tax matters by Century City partner Samuel Weiner with associate Seung Yang; on intellectual property and data privacy matters by San Diego counsel Darryl Steensma and Bay Area counsel Robert Blamires with associates Kathryn Parsons-Reponte and Michael Sweeney; on antitrust matters by Washington, D.C. partner Jason Cruise and Washington, D.C. counsel Patrick English; on FDA matters by Washington, D.C. partner Elizabeth Richards with associate Kathryn Culver; on insurance matters by Los Angeles partner Drew Levin with associate Harrison White; and on CFIUS matters by Washington, D.C. partner Jim Barker. 

Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.